Amylin 4Q10 4Q Revenues: $174 million (-6%) 4Q Loss: $19 million (loss of $50 million in 4Q09) FY Revenues: $669 million (-12%) FY Loss: $152 million (loss of $13 million in FY09) Comments: Byetta sales dropped 16% in 4Q10 to $136 million, while Symlin sales rose 24% to $26 million. The company paid Lilly $63 million in profit sharing in 4Q10, down from $75 million. For FY10, Byetta sales fell 16% to $559 million, while Symlin sales were up 6% to $92 million. Cost of goods sold (C...